Jaguar Health (NASDAQ:JAGX) Downgraded by StockNews.com

StockNews.com cut shares of Jaguar Health (NASDAQ:JAGX) from a hold rating to a sell rating in a research report report published on Monday.

Jaguar Health Stock Performance

Shares of JAGX stock opened at $3.86 on Monday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.39 and a current ratio of 1.89. The business has a fifty day moving average of $8.91 and a 200 day moving average of $7.22. Jaguar Health has a 1 year low of $3.07 and a 1 year high of $41.76.

Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share (EPS) for the quarter. The firm had revenue of $2.35 million during the quarter. Jaguar Health had a negative return on equity of 642.15% and a negative net margin of 377.95%. Equities research analysts anticipate that Jaguar Health will post -5.42 earnings per share for the current fiscal year.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.